The Preclinical Stage Partnering Terms and
Agreements 2010-2015 report provides comprehensive understanding and
unprecedented access to the preclinical stage partnering deals and agreements
entered into by the worlds leading healthcare companies.
Description
The Preclinical Stage Partnering Terms and
Agreements 2010-2015 report provides comprehensive understanding and
unprecedented access to the preclinical stage partnering deals and agreements
entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and
analysis of how and why companies enter preclinical stage partnering deals. The
majority of deals are where the licensee obtains a right or an option right to
license the licensors product or compound. These deals tend to be multicomponent,
starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest
preclinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective
partner’s negotiated deals terms provides critical insight into the negotiation
process in terms of what you can expect to achieve during the negotiation of
terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered –
contract documents provide this insight where press releases and databases do
not.
This report contains a comprehensive listing of all
preclinical stage partnering deals announced since 2010 including financial
terms where available including over 2,000 links to online deal records of
actual preclinical partnering deals as disclosed by the deal parties. In
addition, where available, records include contract documents as submitted to
the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an
orientation of preclinical stage deal making and business activities.
Chapter 1 provides an introduction to the report,
whilst
Chapter 2 provides an overview of why companies
partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage
deals strategy and deal structure including numerous case studies.
Chapter 4 provides an overview of the various
payment strategies used in preclinical stage deals.
Chapter 5 provides a review of trends in
preclinical stage deal making since 2010. Deals are listed by big pharma and
big biotech dealmaking in preclinical stage, deal type, therapy type and
technology type.
Chapter 6 provides a detailed analysis of
preclinical stage payment terms including average headline, upfront, milestone
and royalty rates for preclinical deals.
Chapter 7 provides a review of the leading preclinical
stage deal by headline value.
Chapter 8 provides a comprehensive listing of the
top 50 big pharma and top 50 big biotech companies with a brief summary
followed by a comprehensive listing of preclinical stage deals, as well as
contract documents available in the public domain. Where available, each deal
title links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand.
Chapter 9 provides a comprehensive and detailed
review of preclinical stage partnering deals signed and announced since 2010,
where a contract document is available in the public domain. The chapter is
organized by company A-Z, stage of development at signing, deal type (collaborative
R&D, co-promotion, licensing etc), and specific therapy focus. Each deal
title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract
document on demand.
Chapter 10 provides a comprehensive directory of
preclinical stage partnering deals since 2010 organized by stage of development
– preclinical.
The report also includes numerous tables and
figures that illustrate the trends and activities in preclinical stage
partnering and deal making since 2010.
In addition, a comprehensive appendix is provided
organized by partnering company A-Z , deal type, therapy focus and technology
type. Each deal title links via Weblink to an online version of the deal record
and where available, the contract document, providing easy access to each
contract document on demand.
In conclusion, this report provides everything a
prospective dealmaker needs to know about partnering in the research,
development and commercialization of preclinical stage products and compounds.
Benefits
Preclinical Stage Partnering Terms and
Agreements 2010-2015 provides the reader with the following key benefits:
- In-depth understanding of preclinical stage deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 2,000 preclinical stage deals together with contract documents if available
- Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Identify leading preclinical stage deals by value since 2010
- Identify the most active preclinical stage dealmakers since 2010
- Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 2189 pages and 47
Figures “Preclinical
Stage Partnering Terms and Agreements 2010-2015” report covers Executive
Summary, Introduction, Why do companies partner preclinical stage compounds?,
Preclinical stage deal strategies and structure, Preclinical stage partnering
payment strategies, Trends in preclinical stage deal making, Average payment
terms for preclinical stage partnering, Leading preclinical stage deals, Big pharma and big biotech preclinical stage
partnering deals, Preclinical stage partnering contracts directory, Preclinical
stage dealmaking directory, Appendix.
Find
more information Visit at: http://mrr.cm/o67
Find all Healthcare Report visit at - http://www.marketresearchreports.com/healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.